<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739632</url>
  </required_header>
  <id_info>
    <org_study_id>HYP202-CTP</org_study_id>
    <nct_id>NCT03739632</nct_id>
  </id_info>
  <brief_title>Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo Controlled Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets in Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Synergy Pharmaceutical Sciences Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Synergy Pharmaceutical Sciences Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of Hypidone Hydrochloride
      tablets in treatment of patients with major depressive disorder (MDD) by evaluating the
      change of MADRS total scores from baseline to week 6.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 240 major depressive disorder (MDD) subjects between the ages of 18-65 who have
      current major depressive disorder diagnosed by DSM-5 will be recruited, Eligible patients
      will be randomized with a 1:1:1:1 ratio into the 4 treatment arms to receive either Hypidone
      Hydrochloride tablets or placebo, and will be accepted into the protocol after review and
      providing voluntary written informed consent forms and completion of a comprehensive medical
      and psychiatric history, physical examination, mental status examination, and routine
      laboratory assessment.

      The subjects will accept the drug treatment twice daily orally for 6 weeks. During the
      treatment follow up will occur at 8±1 days after treatment, 15±1 days after treatment, 29±2
      days after treatment , 43±2 days after treatment to evaluate the safety and efficacy of the
      drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Actual">December 23, 2019</completion_date>
  <primary_completion_date type="Actual">December 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline,43 days after treatment</time_frame>
    <description>Change from baseline in MADRS scores，the *total* score ranges[0,60],higher values represent a worse outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Scale 17 items(HAMD17)</measure>
    <time_frame>Baseline,43 days after treatment</time_frame>
    <description>Change from baseline in HAMD17 scores,the *total* score ranges[0,50],higher values represent a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAM-A)</measure>
    <time_frame>Baseline,43 days after treatment</time_frame>
    <description>Change from baseline in HAM-A scores,the *total* score ranges[0,56],higher values represent a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Severity Scale(CGI-S)</measure>
    <time_frame>Screening,Baseline, 8 day after treatment,15 day after treatment,29 day after treatment,43 day after treatment</time_frame>
    <description>Change from baseline in CGI-S scores,the *total* score ranges[0,7],higher values represent a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement Scale(CGI-I)</measure>
    <time_frame>8 day after treatment,15 day after treatment,29 day after treatment,43 day after treatment</time_frame>
    <description>the *total* score ranges[0,7],higher values represent a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Digit Symbol Substitution Test (DSST)</measure>
    <time_frame>Baseline, 43 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Trail Making Test Parts A&amp;B (TMT)</measure>
    <time_frame>Baseline, 43 days after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>10 mg of Hypidone Hydrochloride tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypidone Hydrochloride tablets 10mg/day Study,5mg tablet is to be given orally, twice daily, for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg of Hypidone Hydrochloride tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypidone Hydrochloride tablets 20mg/day Study,10mg tablet is to be given orally, twice daily, for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg of Hypidone Hydrochloride tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypidone Hydrochloride tablets 40mg/day Study,20mg tablet is to be given orally, twice daily, for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets is to be given orally, twice daily, for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypidone Hydrochloride tablets</intervention_name>
    <description>Hypidone Hydrochloride tablets will be given orally, twice daily, for 6 weeks</description>
    <arm_group_label>10 mg of Hypidone Hydrochloride tablets</arm_group_label>
    <arm_group_label>20 mg of Hypidone Hydrochloride tablets</arm_group_label>
    <arm_group_label>40 mg of Hypidone Hydrochloride tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets will be given orally, twice daily, for 6 weeks</description>
    <arm_group_label>comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatient or Inpatient, 18-65 years old, male or female

          2. Current major depressive disorder diagnosed by DSM-5, single episode(296.21, 296.22,
             296.23), or recurrent episode(296.31, 296.32, 296.33)

          3. Montgomery-Åsberg Depression Rating Scale (MADRS) total scores in both Screening and
             Baseline ≥ 26

          4. The first item of MADRS in both Screening and Baseline ≥ 3

          5. CGI-S in both Screening and Baseline ≥ 4

          6. Able to provide written informed consent forms

        Exclusion Criteria:

          1. Subjects accord with other mental disorders diagnosed by DSM-5

          2. Subjects who attempted to suicide, or who presently have a high risk of suicide, or
             with the tenth item (Suicidal ideation) of C-SSRS ≥ 3

          3. Baseline total scores compared with the screening period, the reduction rate of MADRS
             ≥ 25%

          4. Subjects with serious or uncontrolled cardiovascular disease, liver disease, kidney
             disease, blood disease, endocrine disease, respiratory disease

          5. Subjects with clinically significant ECG abnormal (Male QTcF ≥ 450 msec, Female QTcF ≥
             470 msec)

          6. Treatment with a MAOI within the 2 weeks prior to the first dose of trial medication

          7. Practicing 2 different treatment methods of antidepressants as recommended dose of
             full course (≥6 weeks)

          8. Subjects who have had a Vagus Nerve Stimulation (VNS) device implanted, or who have
             received Modified Electric Convulsive Therapy (MECT) or Transcranial Magnetic
             Stimulation (TMS) within 3 months of Screening, or who received light treatment, laser
             treatment, acupuncture and other Chinese medicine treatment, biofeedback treatment
             within 2 weeks of Screening

          9. Subjects with a history of true allergic response to more than 1 class of medications

         10. Subjects who participated in a clinical trial within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anding Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Huilongguan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Sixth Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Hui'ai Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hebei Mental Health Center</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Psychiatric Hospital</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Mental Health Center</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Brain Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuxi Mental Health Center</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Mental Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin Neuropsychiatric Hospital</name>
      <address>
        <city>Siping</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Mental Health Center</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xi'an Mental Health Center</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 7th People's Hospital of Hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third People's Hospital of Huzhou</name>
      <address>
        <city>Huzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ningbo Kangning Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

